Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection

Journal of Infectious Diseases

Volumn 195, Issue 2, 2007, Pages 185-193

  Hanniffy, Sean B ^a   Carter, Andrew T ^a   Hitchin, Ed ^a   Wells, Jerry M ^a,b,c  

^a INSTITUTE OF FOOD RESEARCH   (United Kingdom)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; PNEUMOCOCCAL SURFACE PROTEIN A; STREPTOCOCCUS ANTIGEN; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION RESISTANCE; LACTOCOCCUS LACTIS; LUNG LAVAGE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFECTION; SEPSIS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TH1 CELL; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BRONCHOALVEOLAR LAVAGE FLUID; LACTOCOCCUS LACTIS; MICE; MICE, INBRED CBA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RESPIRATORY TRACT INFECTIONS; SEPSIS; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, SYNTHETIC;

EID: 33846141477     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/509807     Document Type: Article

References (60)

1. Obaro S, Adegbola R. The pneumococcus: carriage, disease and conjugate vaccines. J Med Microbiol 2002; 51:98-104.
2. World Health Organization (WHO). WHO report of the Technical Review Group meeting Jun 7-8 1998. Geneva, Switzerland: WHO, 1998.
3. Morita JY, Zell ER, Danila R, et al. Association between antimicrobial resistance among pneumococcal isolates and burden of invasive pneumococcal disease in the community. Clin Infect Dis 2002; 35:420-7.
4. Jacobs MR. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am J Med 2004; 117(Suppl 3A):S3-15.
5. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154:2666-77.
6. Poland GA. The burden of pneumococcal disease: the role of conjugate vaccines. Vaccine 1999; 17:1674-9.
7. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4:144-54.
8. Swiatlo E, Ware D. Novel vaccine strategies with protein antigens of Streptococcus pneumoniae. FEMS Immunol Med Microbiol 2003; 38:1-7.
9. Shinefield HR, Black S. Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr Infect Dis J 2000; 19:394-7.
10. Adams MR, Marteau P. On the safety of lactic acid bacteria from food. Int J Food Microbiol 1995; 27:263-44.
11. Brandtzaeg P. Role of secretory antibodies in the defence against infections. Int J Med Microbiol 2003; 293:3-15.
12. Nouaille S, Ribeiro LA, Miyoshi A, et al. Heterologous protein production and delivery systems for Lactococcus lactis. Genet Mol Res 2003; 2:102-11.
13. Wells JM, Mercenier A. Lactic acid bacteria as mucosal delivery systems. In: Wood BJB, Warner PJ, eds. Genetics of lactic acid bacteria. Dordrecht, The Netherlands: Kluwer Academic/Plenum, 2003:260-91.
14. Hanniffy S, Wiedermann U, Repa A, et al. Potential and opportunities for use of recombinant lactic acid bacteria in human health. Adv Appl Microbiol 2004; 56:1-64.
15. Repa A, Grangette C, Daniel C, et al. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine 2003; 22:87-95.
16. Robinson K, Chamberlain LM, Lopez MC, et al. Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C. Infect Immun 2004; 72:2753-61.
17. Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F, et al. A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005; 175:7297-302.
18. Wells JM, Wilson PW, Norton PM, Gasson MJ, Le Page RW. Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Mol Microbiol 1993; 8:1155-62.
19. Mannam P, Jones KF, Geller BL. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun 2004; 72:3444-50.
20. Cheun HI, Kawamoto K, Hiramatsu M, et al. Protective immunity of SpaA-antigen producing Lactococcus lactis against Erysipelothrix rhusiopathiae infection. J Appl Microbiol 2004; 96:1347-53.
21. Corthésy B, Boris S, Isler P, Grangette C, Mercenier A. Oral immunization of mice with lactic acid bacteria producing Helicobacter pylori urease B subunit partially protects against challenge with Helicobacter felis. J Infect Dis 2005; 192:1441-9.
22. Xin KQ, Hoshino Y, Toda Y, et al. Immunogenicity and protective efficacy of orally administered recombin ant Lactococcus lactis expressing surface-bound HIV Env. Blood 2003; 102:223-8.
23. McDaniel LS, Ralph BA, McDaniel DO, Briles DE. Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog 1994; 17:323-37.
24. McCool TL, Gate TR, Moy G, Weiser JN. The immune response to pneumococcal proteins during experimental human carriage. J Exp Med 2002; 195:359-65.
25. Hollingshead SK, Becker R, Briles DE. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 2000; 68:5889-900.
26. Nabors GS, Braun PA, Herrmann DJ, et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 2000; 18:1743-54.
27. Briles DE, Hollingshead SK, King J, et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 2000; 182:1694-701.
28. Kadioglu A, Gingles NA, Grattan K, Kerr A, Mitchell TJ, Andrew PW. Host cellular immune response to pneumococcal lung infection in mice. Infect Immun 2000; 68:492-501.
29. Aaberge IS, Eng J, Lermark G, Lovik M. Virulence of Streptococcus pneumoniae in mice: a standardized method for preparation and frozen storage of the experimental bacterial inoculum. Microb Pathog 1995; 18:141-52.
30. Gasson MJ. Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing. J Bacteriol 1983; 154:1-9.
31. Dodd HM, Horn N, Chan WC, et al. Molecular analysis of the regulation of nisin immunity. Microbiology 1996; 142:2385-92.
32. Wells JM, Wilson PW, Le Page RW Improved cloning vectors and transformation procedure for Lactococcus lactis. J Appl Bacteriol 1993; 74:629-36.
33. Robinson K, Chamberlain LM, Schofield KM, Wells JM, Le Page RW. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat Biotechnol 1997; 15:653-7.
34. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54.
35. Reuter MA, Hanniffy S, Wells JM. Expression and delivery of heterologous antigens using lactic acid bacteria. Methods Mol Med 2003; 87:101-14.
36. de Ruyter PG, Kuipers OP, Beerthuyzen MM, van Alen-Boerrigter I, de Vos WM. Functional analysis of promoters in the nisin gene cluster of Lactococcus lactis. J Bacteriol 1996; 178:3434-9.
37. Seepersaud R, Hanniffy SB, Mayne P, Sizer P, Le Page R, Wells JM. Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity. Infect Immun 2005; 73:1671-83.
38. Ahren C, Wenneras C, Holmgren J, Svennerholm AM. Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine. Vaccine 1993; 11:929-34.
39. Yother J, Handsome GL, Briles DE. Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J Bacteriol 1992; 174:610-8.
40. Nayak AR, Tinge SA, Tart RC, McDaniel LS, Briles DE, Curtiss R 3rd. A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect Immun 1998; 66:3744-51.
41. Talkington DF, Voellinger DC, McDaniel LS, Briles DE. Analysis of pneumococcal PspA microheterogeneity in SDS polyacrylamide gels and the association of PspA with the cell membrane. Microb Pathog 1992; 13:343-55.
42. Lobaina Y, Garcia D, Abreu N, Muzio V, Aguilar JC. Mucosal immunogenicity of the hepatitis B core antigen. Biochem Biophys Res Commun 2003; 300:745-50.
43. Roche H, Hakansson A, Hollingshead SK, Briles DE. Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model. Infect Immun 2003; 71:1033-41.
44. Roche H, Ren B, McDaniel LS, Hakansson A, Briles DE. Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae. Infect Immun 2003; 71:4498-505.
45. Miyaji EN, Dias WO, Tanizaki MM, Leite LC. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses. FEMS Immunol Med Microbiol 2003; 37:53-7.
46. Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 2001; 69:6718-24.
47. Guckian JC, Christensen GD, Fine DP. The role of opsonins in recovery from experimental pneumococcal pneumonia. J Infect Dis 1980; 142:175-90.
48. Hof DG, Repine JE, Giebink GS, Hoidal JR. Production of opsonins that facilitate phagocytosis of Streptococcus pneumoniae by human alveolar macrophages or neutrophils after vaccination with pneumococcal polysaccharide. Am Rev Respir Dis 1981; 124:193-5.
49. Gordon SB, Irving GR, Lawson RA, Lee ME, Read RC. Intracellular trafficking and killing of Streptococcus pneumoniae by human alveolar macrophages are influenced by opsonins. Infect Immun 2000; 68:2286-93.
50. Kemp K, Bruunsgaard H, Skinhoj P, Klarlund Pedersen B. Pneumococcal infections in humans are associated with increased apoptosis and trafficking of type 1 cytokine-producing T cells. Infect Immun 2002; 70:5019-25.
51. Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA 2005; 102:4848-53.
52. Kadioglu A, Andrew PW. The innate immune response to pneumococcal lung infection: the untold story. Trends Immunol 2004; 25:143-9.
53. Gluck U, Gebbers JO. Ingested probiotics reduce nasal colonization with pathogenic bacteria (Staphylococcus aureus, Streptococcus pneumoniae, and beta-hemolytic streptococci). Am J Clin Nutr 2003; 77:517-20.
54. Hatakka K, Savilahti E, Ponka A, et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ 2001; 322:1327.
55. Rio ME, Zago Beatriz L, Garcia H, Winter L. [The nutritional status change the effectiveness of a dietary supplement of lactic bacteria on the emerging of respiratory tract diseases in children]. Arch Latinoam Nutr 2002; 52:29-34.
56. Fang H, Elina T, Heikki A, Seppo S. Modulation of humoral immune response through probiotic intake. FEMS Immunol Med Microbiol 2000; 29:47-52.
57. Cangemi de Gutierrez R, Santos V, Nader-Macias ME. Protective effect of intranasally inoculated Lactobacillus fermentum against Streptococcus pneumoniae challenge on the mouse respiratory tract. FEMS Immunol Med Microbiol 2001; 31:187-95.
58. Matsuguchi T, Takagi A, Matsuzaki T, et al. Lipoteichoic acids from Lactobacillus strains elicit strong tumor necrosis factor alpha-inducing activities in macrophages through Toll-like receptor 2. Clin Diagn Lab Immunol 2003; 10:259-66.
59. Kerr AR, Irvine JJ, Search JJ, et al. Role of inflammatory mediators in resistance and susceptibility to pneumococcal infection. Infect Immun 2002; 70:1547-57.
60. Steidler L, Neirynck S, Huyghebaert N, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003; 21:785-9.